Ultratard Europeiska unionen - svenska - EMA (European Medicines Agency)

ultratard

novo nordisk a/s - insulin human - diabetes mellitus - läkemedel som används vid diabetes - behandling av diabetes mellitus.

Ultrasan vet. Injektionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ultrasan vet. injektionsvätska, lösning

pharmaxim ab - rrr-alfa-tokoferylacetat; ergokalciferol; retinolpalmitat - injektionsvätska, lösning - rrr-alfa-tokoferylacetat 100 mg aktiv substans; retinolpalmitat 100000 ie aktiv substans; etanol, vattenfri hjälpämne; jordnötsolja, raffinerad hjälpämne; ergokalciferol 50000 ie aktiv substans - kombinationer - får, hund, häst, nöt, svin

Ultratard 100 IE/ml INJEKTIONSVÄTSKA Sverige - svenska - Läkemedelsverket (Medical Products Agency)

ultratard 100 ie/ml injektionsvätska

novo nordisk a/s - insulin, humant - injektionsvÄtska - 100 ie/ml - metylparahydroxibensoat hjälpämne; insulin, humant 100 ie aktiv substans - insulin (humant)

Comirnaty Europeiska unionen - svenska - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacciner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. användning av detta vaccin bör ske i enlighet med officiella rekommendationer.

Caverject Dual 10 mikrogram Pulver och vätska till injektionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

caverject dual 10 mikrogram pulver och vätska till injektionsvätska, lösning

pfizer ab - alprostadil - pulver och vätska till injektionsvätska, lösning - 10 mikrogram - bensylalkohol hjälpämne; laktosmonohydrat hjälpämne; alfadex hjälpämne; alprostadil 10 mikrog aktiv substans - alprostadil

Caverject Dual 20 mikrogram Pulver och vätska till injektionsvätska, lösning Sverige - svenska - Läkemedelsverket (Medical Products Agency)

caverject dual 20 mikrogram pulver och vätska till injektionsvätska, lösning

pfizer ab - alprostadil - pulver och vätska till injektionsvätska, lösning - 20 mikrogram - bensylalkohol hjälpämne; alprostadil 20 mikrog aktiv substans; laktosmonohydrat hjälpämne; alfadex hjälpämne - alprostadil